Protein Therapy Aims to Restore Brain Function in Fragile X Syndrome

A bold experiment is underway at the University of California, Riverside, where researchers have secured funding to test whether engineered proteins can correct the abnormal brain activity that lies at the heart of Fragile X syndrome. The one-year, $100,000 grant from the FRAXA Research Foundation will support a pilot study in the laboratory of Dr. Devin Binder, a professor of biomedical sciences in the UCR School of Medicine. The project will evaluate several protein candidates developed by the biotechnology company Bowen’s FX Therapeutics, using a mouse model of the disorder to determine whether the treatments can normalize brain physiology. If successful, the work could open an entirely new therapeutic avenue for a condition that currently has no disease-modifying treatment.

Fragile X syndrome affects roughly 100,000 Americans and is the most common inherited cause of intellectual disability. The disorder stems from changes affecting the FMR1 gene, which disrupts production of FMRP, a protein essential for normal brain development and function. Without adequate FMRP, the brain’s neural circuits develop and operate abnormally, producing a constellation of symptoms that includes intellectual disability, difficulties with learning and memory, social and behavioral challenges, and unusual sensitivity to sensory stimuli such as sound and touch. Fragile X is also recognized as a major genetic contributor to autism spectrum disorder, making advances against the condition relevant far beyond its own patient population.

The central obstacle the collaboration hopes to overcome is one that has frustrated neurologists for decades: the blood-brain barrier. This highly selective interface between the bloodstream and brain tissue blocks the passage of most large molecules, including proteins, which means that even a perfectly designed therapeutic protein is useless if it cannot reach its target cells. Binder explained that Bowen’s FX Therapeutics has used protein engineering to develop versions of the Fragile X-related protein that can be administered systemically, meaning through the bloodstream, and still cross the blood-brain barrier. Once inside the brain, the engineered proteins are designed to replace the function of the protein that is missing or impaired in people with the disorder.

For Binder, the project represents a convergence of two research threads that have matured in parallel: his own years of work characterizing abnormal brain activity in Fragile X, and recent breakthroughs in protein delivery technology. He expressed astonishment at how far the field has come. According to Binder, his collaborators can now engineer a protein and get it into the brain and into cells, something that a few years ago would have seemed like science fiction. That capability, he suggested, transforms what was once a purely observational research program into one that can actively test a potential therapy.

The testing platform for the study is the Fragile X knockout mouse, a well-established animal model in which the gene responsible for the disorder has been removed. These mice exhibit several brain abnormalities that closely resemble those observed in people with Fragile X, including changes in how the brain processes sensory information and how it coordinates neural activity across regions. Because the model recapitulates key features of the human condition, it provides a rigorous preclinical setting in which a candidate therapy can be evaluated before any consideration of human trials.

Binder’s laboratory brings to the collaboration a particular strength in measuring brain activity in living animals, an expertise built over years of studying Fragile X and epilepsy. One of the lab’s principal tools is electroencephalography, or EEG, a technique that records electrical signals generated by neural populations. Rather than examining brain tissue in isolation, the team monitors the whole animal as it behaves and processes stimuli, with the goal of obtaining very high-quality brain recordings from the mice. This approach captures brain function in its natural, dynamic context, which is precisely where the symptoms of Fragile X manifest.

Critically, the lab has already identified specific EEG abnormalities in Fragile X mice, and those measurements now serve as a baseline for the therapeutic study. The logic of the experiment is elegant in its simplicity: if the engineered proteins are doing their job, the characteristic signatures of abnormal brain activity should diminish, and the electrical patterns of treated Fragile X mice should shift toward those of normal mice. Binder and Carrie Jonak, a research associate in the laboratory who generated the preliminary data supporting the grant application and will carry out much of the research, have a straightforward measure of success. As Binder put it, if the Fragile X mice after treatment begin to resemble the normal mice, and their physiology is essentially normalized, that would be a very significant result.

The pilot study is deliberately scoped as a first step rather than a definitive test of clinical benefit. It will not directly determine whether treated mice become better at learning or remembering, since cognitive and behavioral assessments fall outside the one-year project’s scope. However, the researchers argue that brain physiology is upstream of behavior: if the treatment corrects the electrical abnormalities in neural circuits, Binder said his team would predict that some of the associated cognitive and behavioral problems could also improve. In this way, EEG normalization serves as an early, quantifiable biomarker of therapeutic effect, potentially accelerating the path toward more comprehensive studies.

Beyond its scientific promise, the project is also a case study in how targeted foundation funding can bridge the gap between academic neuroscience and biotechnology. Binder framed the collaboration as an example of how foundation support can bring together complementary partners that would not otherwise connect. Bowen’s FX Therapeutics provides access to a promising therapeutic technology, while his laboratory contributes expertise in measuring brain activity in living animals. As he noted, academics would not necessarily have access to these kinds of therapeutics on their own. For a disorder that has resisted every conventional pharmacological approach, the combination of engineered proteins capable of crossing the blood-brain barrier and sensitive physiological readouts in a validated animal model offers a genuinely new strategy, and one whose first results could reshape expectations for treating Fragile X syndrome.

Subject of Research: Protein-based therapy research for Fragile X syndrome

Article Title: Testing a new approach to treating Fragile X

Article References: Testing a new approach to treating Fragile X. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Fragile X syndrome, FMR1 gene, FMRP, protein engineering, blood-brain barrier, electroencephalography, mouse model, FRAXA Research Foundation, UC Riverside, neuroscience, autism spectrum disorder, biotechnology